Literature DB >> 15653941

Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder.

D P Devanand1, Mitchell S Nobler, Jocelyn Cheng, Nancy Turret, Gregory H Pelton, Steven P Roose, Harold A Sackeim.   

Abstract

OBJECTIVE: The authors compared the efficacy and side effects of fluoxetine and placebo in elderly outpatients with dysthymic disorder.
METHODS: Patients were randomly assigned to fluoxetine (20 mg-60 mg/day) or placebo for 12 weeks in a double-blind trial.
RESULTS: Of 90 randomized patients, 71 completed the trial. In the intent-to-treat sample, random regression analyses of the Hamilton Rating Scale for Depression (Ham-D; 24-item) and Cornell Dysthymia Rating Scale (CDRS) scores at each visit produced significant time x treatment group interactions favoring the fluoxetine group. Analysis of percentage change in Ham-D scores yielded no effect for treatment group, but a similar analysis of percentage change in CDRS scores yielded a main effect for treatment group, favoring fluoxetine over placebo. In the intent-to-treat sample, response rates were 27.3% for fluoxetine and 19.6% for placebo. In the completer sample, response rates were 37.5% for fluoxetine and 23.1% for placebo.
CONCLUSION: Fluoxetine had limited efficacy in elderly dysthymic patients. The clinical features of elderly dysthymic patients are typically distinct from those of dysthymic disorder in young adults, and the findings suggest that treatments effective for young adult dysthymic patients may not be as useful in elderly dysthymic patients. Further research is needed to identify efficacious treatments for elderly patients with dysthymic disorder, and investigative tools such as electronic/computerized brain scans and neuropsychological testing may help identify the factors that moderate antidepressant treatment response and resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653941     DOI: 10.1176/appi.ajgp.13.1.59

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  8 in total

Review 1.  How should primary care doctors select which antidepressants to administer?

Authors:  Gerald Gartlehner; Kylie Thaler; Seth Hill; Richard A Hansen
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 2.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 3.  Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults.

Authors:  Glenda MacQueen; Pasqualina Santaguida; Homa Keshavarz; Natalia Jaworska; Mitchell Levine; Joseph Beyene; Parminder Raina
Journal:  Can J Psychiatry       Date:  2016-09-24       Impact factor: 4.356

4.  Dysthymia and apathy: diagnosis and treatment.

Authors:  Junko Ishizaki; Masaru Mimura
Journal:  Depress Res Treat       Date:  2011-06-27

5.  The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.

Authors:  Gemma Lewis; Larisa Duffy; Anthony Ades; Rebekah Amos; Ricardo Araya; Sally Brabyn; Katherine S Button; Rachel Churchill; Catherine Derrick; Christopher Dowrick; Simon Gilbody; Christopher Fawsitt; William Hollingworth; Vivien Jones; Tony Kendrick; David Kessler; Daphne Kounali; Naila Khan; Paul Lanham; Jodi Pervin; Tim J Peters; Derek Riozzie; George Salaminios; Laura Thomas; Nicky J Welton; Nicola Wiles; Rebecca Woodhouse; Glyn Lewis
Journal:  Lancet Psychiatry       Date:  2019-09-19       Impact factor: 27.083

6.  The effects of selective serotonin reuptake inhibitors on memory functioning in older adults: A systematic literature review.

Authors:  Julie Em Schulkens; Kay Deckers; Maud Jenniskens; Arjan Blokland; Frans Rj Verhey; Sjacko Sobczak
Journal:  J Psychopharmacol       Date:  2022-04-29       Impact factor: 4.562

7.  Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000-2020: A systematic review and meta-analysis.

Authors:  Yi-Hsuan Lin; Ethan Sahker; Kiyomi Shinohara; Noboru Horinouchi; Masami Ito; Madoka Lelliott; Andrea Cipriani; Anneka Tomlinson; Christopher Baethge; Toshi A Furukawa
Journal:  EClinicalMedicine       Date:  2022-07-01

8.  An open treatment trial of duloxetine in elderly patients with dysthymic disorder.

Authors:  Nancy Kerner; Kristina D'Antonio; Gregory H Pelton; Elianny Salcedo; Jennifer Ferrar; Steven P Roose; Dp Devanand
Journal:  SAGE Open Med       Date:  2014-05-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.